Skip to main content
NCBI home page
The American Journal of Pathology logoLink to The American Journal of Pathology
. 1995 Jun;146(6):1368–1375.

Castration therapy rapidly induces apoptosis in a minority and decreases cell proliferation in a majority of human prostatic tumors.

P Westin 1, P Stattin 1, J E Damber 1, A Bergh 1
PMCID: PMC1870920  PMID: 7778676

Abstract

Major differences in the long-term clinical response to castration therapy of prostatic carcinoma suggests intertumoral differences in cellular response and defines a need for identification of patients with an eventually positive outcome as well as those in need of additional treatment. Using morphometry, monoclonal antibodies against Bcl-2, c-myc, Ki-67, and p53 proteins, and an in situ method to visualize apoptotic cells, we examined the short-term response of prostatic tumors to castration in core biopsies from 18 prostatic cancer patients taken the day before and 7 days after castration. At the histological level, 3 tumors seemed practically unaffected by castration. In 15 tumors, castration induced vacuolization of tumor cell cytoplasm and decreases in nuclear area and Ki-67 index. In these 15 tumors, apoptotic index was significantly increased in 6, principally unaffected in 6, and decreased in 3. The 6 tumors responding with an increase in apoptotic index were WHO grade 1 or 2 and negative for p53, c-myc, and Bcl-2 or contained only few Bcl-2- or c-myc-positive tumor cells before therapy. The 12 tumors in which apoptotic index was unaffected or decreased were WHO grade 2 or 3 and immunopositive for one or more of p53, Bcl-2, and c-myc proteins before therapy. The Bcl-2 index was significantly increased in 10 patients. Prostatic tumors may respond in a variety of possibly predictable ways to castration therapy including a decrease in apoptotic index. The magnitude of these responses are not correlated in individual tumors, suggesting that the common classification of prostatic tumors as either androgen dependent (dying after castration) or independent (not responding at all to castration) may be an oversimplification.

Full text

PDF
1368

Images in this article

1370Figure 1
on p.1370
1372Figure 2
on p.1372

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Brändström A., Westin P., Bergh A., Cajander S., Damber J. E. Castration induces apoptosis in the ventral prostate but not in an androgen-sensitive prostatic adenocarcinoma in the rat. Cancer Res. 1994 Jul 1;54(13):3594–3601. [PubMed] [Google Scholar]
  2. Buttyan R., Sawczuk I. S., Benson M. C., Siegal J. D., Olsson C. A. Enhanced expression of the c-myc protooncogene in high-grade human prostate cancers. Prostate. 1987;11(4):327–337. doi: 10.1002/pros.2990110405. [DOI] [PubMed] [Google Scholar]
  3. Carson D. A., Ribeiro J. M. Apoptosis and disease. Lancet. 1993 May 15;341(8855):1251–1254. doi: 10.1016/0140-6736(93)91154-e. [DOI] [PubMed] [Google Scholar]
  4. Colombel M., Symmans F., Gil S., O'Toole K. M., Chopin D., Benson M., Olsson C. A., Korsmeyer S., Buttyan R. Detection of the apoptosis-suppressing oncoprotein bc1-2 in hormone-refractory human prostate cancers. Am J Pathol. 1993 Aug;143(2):390–400. [PMC free article] [PubMed] [Google Scholar]
  5. Dhom G., Degro S. Therapy of prostatic cancer and histopathologic follow-up. Prostate. 1982;3(6):531–542. doi: 10.1002/pros.2990030602. [DOI] [PubMed] [Google Scholar]
  6. Evan G. I., Wyllie A. H., Gilbert C. S., Littlewood T. D., Land H., Brooks M., Waters C. M., Penn L. Z., Hancock D. C. Induction of apoptosis in fibroblasts by c-myc protein. Cell. 1992 Apr 3;69(1):119–128. doi: 10.1016/0092-8674(92)90123-t. [DOI] [PubMed] [Google Scholar]
  7. Isaacs J. T. Antagonistic effect of androgen on prostatic cell death. Prostate. 1984;5(5):545–557. doi: 10.1002/pros.2990050510. [DOI] [PubMed] [Google Scholar]
  8. Isaacs J. T., Lundmo P. I., Berges R., Martikainen P., Kyprianou N., English H. F. Androgen regulation of programmed death of normal and malignant prostatic cells. J Androl. 1992 Nov-Dec;13(6):457–464. [PubMed] [Google Scholar]
  9. Kerr J. F., Searle J. Deletion of cells by apoptosis during castration-induced involution of the rat prostate. Virchows Arch B Cell Pathol. 1973 Jun 25;13(2):87–102. doi: 10.1007/BF02889300. [DOI] [PubMed] [Google Scholar]
  10. Korsmeyer S. J. Bcl-2: a repressor of lymphocyte death. Immunol Today. 1992 Aug;13(8):285–288. doi: 10.1016/0167-5699(92)90037-8. [DOI] [PubMed] [Google Scholar]
  11. Kyprianou N., Isaacs J. T. Activation of programmed cell death in the rat ventral prostate after castration. Endocrinology. 1988 Feb;122(2):552–562. doi: 10.1210/endo-122-2-552. [DOI] [PubMed] [Google Scholar]
  12. Landström M., Bergh A., Tomic R., Damber J. E. Estrogen treatment combined with castration inhibits tumor growth more effectively than castration alone in the Dunning R3327 rat prostatic adenocarcinoma. Prostate. 1990;17(1):57–68. doi: 10.1002/pros.2990170107. [DOI] [PubMed] [Google Scholar]
  13. Lowe S. W., Ruley H. E., Jacks T., Housman D. E. p53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell. 1993 Sep 24;74(6):957–967. doi: 10.1016/0092-8674(93)90719-7. [DOI] [PubMed] [Google Scholar]
  14. McDonnell T. J., Troncoso P., Brisbay S. M., Logothetis C., Chung L. W., Hsieh J. T., Tu S. M., Campbell M. L. Expression of the protooncogene bcl-2 in the prostate and its association with emergence of androgen-independent prostate cancer. Cancer Res. 1992 Dec 15;52(24):6940–6944. [PubMed] [Google Scholar]
  15. Miyashita T., Krajewski S., Krajewska M., Wang H. G., Lin H. K., Liebermann D. A., Hoffman B., Reed J. C. Tumor suppressor p53 is a regulator of bcl-2 and bax gene expression in vitro and in vivo. Oncogene. 1994 Jun;9(6):1799–1805. [PubMed] [Google Scholar]
  16. Mostofi F. K., Sesterhenn I. A., Davis C. J., Jr Prostatic carcinoma: problems in the interpretation of prostatic biopsies. Hum Pathol. 1992 Mar;23(3):223–241. doi: 10.1016/0046-8177(92)90103-a. [DOI] [PubMed] [Google Scholar]
  17. Murphy W. M., Soloway M. S., Barrows G. H. Pathologic changes associated with androgen deprivation therapy for prostate cancer. Cancer. 1991 Aug 15;68(4):821–828. doi: 10.1002/1097-0142(19910815)68:4<821::aid-cncr2820680426>3.0.co;2-s. [DOI] [PubMed] [Google Scholar]
  18. Resnick M. I., Grayhack J. T. Treatment of stage IV carcinoma of the prostate. Urol Clin North Am. 1975 Feb;2(1):141–161. [PubMed] [Google Scholar]
  19. Taylor C. R., Shi S. R., Chaiwun B., Young L., Imam S. A., Cote R. J. Strategies for improving the immunohistochemical staining of various intranuclear prognostic markers in formalin-paraffin sections: androgen receptor, estrogen receptor, progesterone receptor, p53 protein, proliferating cell nuclear antigen, and Ki-67 antigen revealed by antigen retrieval techniques. Hum Pathol. 1994 Mar;25(3):263–270. doi: 10.1016/0046-8177(94)90198-8. [DOI] [PubMed] [Google Scholar]
  20. Thalmann G. N., Anezinis P. E., Chang S. M., Zhau H. E., Kim E. E., Hopwood V. L., Pathak S., von Eschenbach A. C., Chung L. W. Androgen-independent cancer progression and bone metastasis in the LNCaP model of human prostate cancer. Cancer Res. 1994 May 15;54(10):2577–2581. [PubMed] [Google Scholar]
  21. Visakorpi T., Kallioniemi O. P., Heikkinen A., Koivula T., Isola J. Small subgroup of aggressive, highly proliferative prostatic carcinomas defined by p53 accumulation. J Natl Cancer Inst. 1992 Jun 3;84(11):883–887. doi: 10.1093/jnci/84.11.883. [DOI] [PubMed] [Google Scholar]
  22. Wagner A. J., Small M. B., Hay N. Myc-mediated apoptosis is blocked by ectopic expression of Bcl-2. Mol Cell Biol. 1993 Apr;13(4):2432–2440. doi: 10.1128/mcb.13.4.2432. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Westin P., Bergh A., Damber J. E. Castration rapidly results in a major reduction in epithelial cell numbers in the rat prostate, but not in the highly differentiated Dunning R3327 prostatic adenocarcinoma. Prostate. 1993;22(1):65–74. doi: 10.1002/pros.2990220109. [DOI] [PubMed] [Google Scholar]
  24. Wijsman J. H., Jonker R. R., Keijzer R., van de Velde C. J., Cornelisse C. J., van Dierendonck J. H. A new method to detect apoptosis in paraffin sections: in situ end-labeling of fragmented DNA. J Histochem Cytochem. 1993 Jan;41(1):7–12. doi: 10.1177/41.1.7678025. [DOI] [PubMed] [Google Scholar]
  25. Wolf D. A., Kohlhuber F., Schulz P., Fittler F., Eick D. Transcriptional down-regulation of c-myc in human prostate carcinoma cells by the synthetic androgen mibolerone. Br J Cancer. 1992 Mar;65(3):376–382. doi: 10.1038/bjc.1992.76. [DOI] [PMC free article] [PubMed] [Google Scholar]
  26. Yonish-Rouach E., Grunwald D., Wilder S., Kimchi A., May E., Lawrence J. J., May P., Oren M. p53-mediated cell death: relationship to cell cycle control. Mol Cell Biol. 1993 Mar;13(3):1415–1423. doi: 10.1128/mcb.13.3.1415. [DOI] [PMC free article] [PubMed] [Google Scholar]
  27. Zhang X., Colombel M., Raffo A., Buttyan R. Enhanced expression of p53 mRNA and protein in the regressing rat ventral prostate gland. Biochem Biophys Res Commun. 1994 Feb 15;198(3):1189–1194. doi: 10.1006/bbrc.1994.1168. [DOI] [PubMed] [Google Scholar]
  28. van Weerden W. M., van Kreuningen A., Elissen N. M., Vermeij M., de Jong F. H., van Steenbrugge G. J., Schröder F. H. Castration-induced changes in morphology, androgen levels, and proliferative activity of human prostate cancer tissue grown in athymic nude mice. Prostate. 1993;23(2):149–164. doi: 10.1002/pros.2990230208. [DOI] [PubMed] [Google Scholar]

Articles from The American Journal of Pathology are provided here courtesy of American Society for Investigative Pathology

RESOURCES